2022 - Research.com Best Female Scientist Award
Ritsuko Komaki spends much of her time researching Radiation therapy, Lung cancer, Surgery, Internal medicine and Oncology. Her research in Radiation therapy intersects with topics in Nuclear medicine, Carcinoma, Lung and Chemotherapy. Her work investigates the relationship between Chemotherapy and topics such as Clinical trial that intersect with problems in Vinblastine.
Her research integrates issues of Cancer, Respiratory disease, Randomized controlled trial, Radiosurgery and Pneumonitis in her study of Lung cancer. In her study, Hazard ratio is inextricably linked to Proportional hazards model, which falls within the broad field of Oncology. Her Radiology research also works with subjects such as
Ritsuko Komaki focuses on Radiation therapy, Internal medicine, Lung cancer, Oncology and Surgery. Ritsuko Komaki interconnects Nuclear medicine, Cancer, Carcinoma and Chemotherapy in the investigation of issues within Radiation therapy. Her research brings together the fields of Gastroenterology and Internal medicine.
She combines subjects such as Stage, Pneumonitis and Hazard ratio with her study of Lung cancer. The Oncology study combines topics in areas such as Clinical trial, Phases of clinical research and Randomized controlled trial. Her Radiology research incorporates themes from Esophagus and Lung.
Her primary scientific interests are in Internal medicine, Radiation therapy, Oncology, Lung cancer and Surgery. Ritsuko Komaki works mostly in the field of Internal medicine, limiting it down to topics relating to Gastroenterology and, in certain cases, Definitive chemoradiotherapy and Toxicity. Her Radiation therapy research is multidisciplinary, incorporating perspectives in Stage, Clinical trial and Nuclear medicine.
The concepts of her Oncology study are interwoven with issues in Survival rate, Multivariate analysis and Chemotherapy. Her study in Lung cancer is interdisciplinary in nature, drawing from both Cancer research, Carcinoma, Immunology and Hazard ratio. Her work on Retrospective cohort study, Randomized controlled trial and Common Terminology Criteria for Adverse Events as part of general Surgery research is often related to SABR volatility model, thus linking different fields of science.
Ritsuko Komaki mainly investigates Radiation therapy, Internal medicine, Lung cancer, Oncology and Surgery. Her Radiation therapy research is classified as research in Radiology. In general Internal medicine study, her work on Esophageal cancer, Chemoradiotherapy and Carcinoma often relates to the realm of In patient, thereby connecting several areas of interest.
Her Lung cancer research is multidisciplinary, incorporating elements of Cancer, Cancer research, Survival rate, Immunology and Lung. Her biological study spans a wide range of topics, including Carboplatin, Combined Modality Therapy, Pembrolizumab and Stage. Ritsuko Komaki usually deals with Surgery and limits it to topics linked to Confidence interval and Primary tumor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide
Andrew T. Turrisi;Kyungmann Kim;Ronald Blum;William T. Sause.
The New England Journal of Medicine (1999)
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley;Rebecca Paulus;Ritsuko Komaki;Gregory Masters.
Lancet Oncology (2015)
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.
Bruce D. Minsky;Thomas F. Pajak;Robert J. Ginsberg;Thomas M. Pisansky.
Journal of Clinical Oncology (2002)
A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung Cancer
Jack A Roth;Frank V Fossella;Ritsuko Komaki;M. Bernadette Ryan.
Journal of the National Cancer Institute (1994)
Non–Small Cell Lung Cancer
David S. Ettinger;Wallace Akerley;Gerold Bepler;Andrew Chang.
Journal of The National Comprehensive Cancer Network (2010)
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y Chang;Suresh Senan;Marinus A. Paul;Reza John Mehran.
Lancet Oncology (2015)
Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
Walter J. Curran;Rebecca Paulus;Corey J. Langer;Ritsuko Komaki.
Journal of the National Cancer Institute (2011)
Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary Results of a Phase III Trial in Regionally Advanced, Unresectable Non-Small-Cell Lung Cancer
William T. Sause;Charles Scott;Samuel Taylor;David H Johnson.
Journal of the National Cancer Institute (1995)
Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
William Sause;Patricia Kolesar;Samuel Taylor;David H Johnson.
Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology
David S. Ettinger;Douglas E. Wood;Dara L. Aisner;Wallace Akerley.
Journal of The National Comprehensive Cancer Network (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: